Results 251 to 260 of about 232,901 (341)

A Human Model of Oligodendrocyte Development Shows MCL‐1 Influences Oligodendrocyte Morphogenesis

open access: yesGlia, Volume 74, Issue 2, February 2026.
A unified model of oligodendrocyte differentiation from human embryonic stem cells revealed that MCL‐1 is critical for regulating the expression of oligodendrocyte‐related genes and the morphogenesis of myelinating oligodendrocytes. ABSTRACT Oligodendrocytes are the myelinating cells of the central nervous system.
Melanie Gil   +2 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo   +11 more
wiley   +1 more source

Mitochondrial Intercellular Transfer via Platelets After Physical Training Exerts Neuro‐Glial Protection Against Cerebral Ischemia

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Treadmill training protects against white matter injury and reduces cerebral infarction. Muscle‐derived mitochondrial transfer via platelets is promoted by treadmill training. Platelet transfusion emerges as a potential low‐risk therapeutic strategy for sequelae and vascular dementia.
Toshiki Inaba   +8 more
wiley   +1 more source

Profound Cognitive Impairment as a Salient Feature of Multiple Sclerosis: A Case Report

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Background Cognitive impairment affects up to two‐thirds of patients with multiple sclerosis (MS); however, profound global deficits, defined as a full‐scale IQ below 70, are uncommon and rarely constitute the primary symptom. Case Presentation We describe a 27‐year‐old woman with severe multidomain cognitive impairment due to MS ...
Shota Ito   +3 more
wiley   +1 more source

Evaluation of the effectiveness and safety of ONO‐2910 for the treatment of diabetic polyneuropathy: An early Phase IIa, multicenter, randomized, placebo‐controlled, double‐blind study in Japanese patients

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 2, Page 310-320, February 2026.
ABSTRACT Aims/Introduction Diabetic polyneuropathy (DPN) is common in patients with diabetes. Its symptoms include pain, numbness, and impaired neurosensory function. ONO‐2910 promotes Schwann cell differentiation and is being developed for DPN. Materials and Methods This Phase IIa randomized controlled trial evaluated the effectiveness and safety of ...
Yukiko Onishi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy